Advisory Resource Group Has $991,000 Stake in Axon Enterprise, Inc (NASDAQ:AXON)

Advisory Resource Group grew its position in Axon Enterprise, Inc (NASDAQ:AXON) by 10.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,884 shares of the biotechnology company’s stock after purchasing an additional 185 shares during the quarter. Advisory Resource Group’s holdings in Axon Enterprise were worth $991,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC acquired a new stake in Axon Enterprise during the 4th quarter worth about $480,000. Principal Securities Inc. boosted its position in shares of Axon Enterprise by 255.7% during the 4th quarter. Principal Securities Inc. now owns 1,085 shares of the biotechnology company’s stock valued at $645,000 after purchasing an additional 780 shares in the last quarter. Allworth Financial LP grew its stake in Axon Enterprise by 23.5% during the fourth quarter. Allworth Financial LP now owns 1,242 shares of the biotechnology company’s stock worth $755,000 after purchasing an additional 236 shares during the period. CIBC Asset Management Inc increased its holdings in Axon Enterprise by 127.0% in the fourth quarter. CIBC Asset Management Inc now owns 24,013 shares of the biotechnology company’s stock worth $14,271,000 after purchasing an additional 13,435 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in Axon Enterprise by 2.7% in the fourth quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 21 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AXON has been the subject of several recent analyst reports. Northcoast Research downgraded shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 19th. Bank of America lifted their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the company a “buy” rating in a research note on Wednesday, June 4th. Craig Hallum cut shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a research report on Monday, March 10th. The Goldman Sachs Group raised their target price on Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Finally, Barclays upped their price target on Axon Enterprise from $726.00 to $735.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $699.55.

Axon Enterprise Stock Down 0.9%

Shares of NASDAQ:AXON opened at $770.79 on Thursday. The business’s 50 day moving average is $683.57 and its 200 day moving average is $624.47. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $806.64. The stock has a market cap of $60.01 billion, a price-to-earnings ratio of 186.18, a PEG ratio of 89.50 and a beta of 1.29. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The firm had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the prior year, the business posted $1.15 EPS. The business’s revenue was up 31.3% compared to the same quarter last year. On average, sell-side analysts forecast that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, President Joshua Isner sold 905 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total transaction of $702,632.95. Following the completion of the sale, the president now directly owns 268,735 shares of the company’s stock, valued at approximately $208,643,166.65. This trade represents a 0.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction on Monday, April 21st. The shares were sold at an average price of $540.99, for a total value of $5,409,900.00. Following the completion of the transaction, the chief executive officer now owns 3,063,982 shares of the company’s stock, valued at $1,657,583,622.18. This trade represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 44,642 shares of company stock valued at $30,500,428 in the last 90 days. 4.40% of the stock is currently owned by corporate insiders.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.